A Look Back at Branded Pharmaceuticals Stocks' Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let's take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q4.
The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in research and development to create innovative, patent-protected drugs. Successful products can generate significant revenue streams over their patent life, and the larger a roster of drugs, the stronger a moat a company enjoys. However, the business model is inherently risky, with high failure rates during clinical trials, lengthy regulatory approval processes, and intense competition from generic and biosimilar manufacturers once patents expire. These challenges, combined with scrutiny over drug pricing, create a complex operating environment. Looking ahead, the industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing.
The 11 branded pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 1.3%.
In light of this news, share prices of the companies have held steady as they are up 1.4% on average since the latest earnings results.
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ:COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Collegium Pharmaceutical reported revenues of $181.9 million, up 21.5% year on year. This print exceeded analysts' expectations by 1%. Overall, it was a strong quarter for the company with a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations.
'2024 was a year of strong execution for Collegium, marked by robust performance in our pain portfolio and the addition of Jornay PM, establishing our presence in neuropsychiatry and reaffirming our commitment to helping improve the lives of people living with serious medical conditions. This was made possible thanks to the dedication of our talented team,' said Vikram Karnani, President and Chief Executive Officer.
The stock is up 6.2% since reporting and currently trades at $30.20.
Is now the time to buy Collegium Pharmaceutical? Access our full analysis of the earnings results here, it's free.
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Supernus Pharmaceuticals reported revenues of $174.2 million, up 6% year on year, outperforming analysts' expectations by 12.2%. The business had a very strong quarter with an impressive beat of analysts' EPS estimates and full-year operating income guidance topping analysts' expectations.
Supernus Pharmaceuticals achieved the biggest analyst estimates beat among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 4.6% since reporting. It currently trades at $31.32.
Is now the time to buy Supernus Pharmaceuticals? Access our full analysis of the earnings results here, it's free.
Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis (NYSE:ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide.
Zoetis reported revenues of $2.32 billion, up 4.7% year on year, in line with analysts' expectations. It was a softer quarter as it posted a significant miss of analysts' full-year EPS guidance estimates.
As expected, the stock is down 6.9% since the results and currently trades at $161.91.
Read our full analysis of Zoetis's results here.
Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself.
Royalty Pharma reported revenues of $594 million, flat year on year. This print lagged analysts' expectations by 1.9%. Overall, it was a slower quarter for the company.
The stock is flat since reporting and currently trades at $31.77.
Read our full, actionable report on Royalty Pharma here, it's free.
Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE:OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines.
Organon reported revenues of $1.59 billion, flat year on year. This number surpassed analysts' expectations by 0.9%. However, it was a slower quarter as it logged full-year revenue guidance missing analysts' expectations.
Organon had the slowest revenue growth among its peers. The stock is down 3.1% since reporting and currently trades at $14.23.
Read our full, actionable report on Organon here, it's free. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Why Tesla (TSLA) Shares Are Trading Lower Today
Shares of electric vehicle pioneer Tesla (NASDAQ:TSLA) fell 4.9% in the afternoon session as momentum slowed after a 40% rally that followed the Q1 2025 selloff, suggesting that the recent surge may have exhausted short-term buying interest. It is also possible some investors were taking profits amid uncertainty as they wait for more concrete updates on Tesla's highly anticipated product updates scheduled for later this year. These updates are critical for improving Tesla's growth story, as reported sales in Europe and China were weak in the first quarter of the year. Contributing to the pullback, a widely circulated Bloomberg report resurfaced concerns about the safety of Tesla's driver-assistance technology, highlighting a fatal 2023 crash. The timing of the story is especially sensitive, as Tesla prepares to unveil its AI-powered robo-taxi service in Austin later in the month, a launch that risked being overshadowed by renewed scrutiny and could shake investor confidence in the company's autonomous driving ambitions. Adding to the wall of worry is Elon Musk increasingly looking like an enemy to President Trump rather than a confidant. President Trump has shown the willingness to punish companies that do not fall in line with his agenda and vision. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tesla? Access our full analysis report here, it's free. Tesla's shares are extremely volatile and have had 131 moves greater than 2.5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 9 days ago when the stock gained 5.2% after the major indices (Nasdaq +2.0%, S&P 500 +1.5%) rebounded as President Trump postponed the planned 50 % tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The update should be beneficial for Tesla, as data from the European Automobile Manufacturers' Association revealed the company sold 7,261 cars in Europe in April, down 49% year on year. So, the delay could help the company avoid being caught in the crossfire of retaliatory tariffs and potential complications from escalating trade tensions between the US and the EU. Contributing to the stock's momentum, CEO Elon Musk noted in a social media post on X (formerly Twitter) that he would be allocating more of his time to the company. He added, "I must be super focused on /xAI and Tesla (plus Starship launch next week), as we have critical technologies rolling out." Tesla is down 19.8% since the beginning of the year, and at $304.24 per share, it is trading 36.6% below its 52-week high of $479.86 from December 2024. Investors who bought $1,000 worth of Tesla's shares 5 years ago would now be looking at an investment worth $5,152. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Nanox AI Bone Solution Receives CE Mark Certification
By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its AI bone solution HealthOST has received CE mark certification which enables its commercialization across Europe. HealthOST examines CT scans to assess vertebral height loss and bone mineral density and helps identify disease risk, such as osteoporosis, before fractures occur, it stated. 'This CE mark for HealthOST represents a significant expansion of our AI capabilities in Europe,' said Erez Meltzer, Nanox CEO and acting Chairman. 'By integrating seamlessly into routine CT scans, HealthOST helps healthcare providers maximize their existing resources, while identifying patients who might otherwise fall through the cracks of traditional screening methods.' Contact: Exec Edge Editor@
Yahoo
25 minutes ago
- Yahoo
Why Micron Stock Popped Today
Mizuho just raised its price target on Micron stock. Mizuho expects Micron to greatly outgrow the rest of the market, boosted by fast-growing sales of high-bandwidth memory for artificial intelligence (AI). 10 stocks we like better than Micron Technology › The stock of semiconductor memory chipmaker -- including for artificial intelligence (AI) server farms -- Micron Technology (NASDAQ: MU) is hopping Thursday morning, up a solid 4.4% through 10:55 a.m. ET. And you can thank the friendly analysts at Mizuho for that. Mizuho raised its price target on Micron stock yesterday after close of trading, reports The Fly, to $130 per share, with an outperform rating. Looking ahead to Micron's fiscal Q2 2025 earnings report, which is expected June 25, Mizuho expects to see strong guidance based on a couple of big numbers. Global sales of high bandwidth memory (HBM) are expected to grow 55% industrywide through 2027, while Micron's sales of HBM are expected to grow 90% annually. That means not only is Micron growing much faster than other memory makers, but it's also probably stealing a lot of market share from its rivals -- both things being great news for Micron stock, if they're correct. The analyst expects this to translate into both sales growth and "margin upside." One hopes that Mizuho's right about that, because as things stand right now, Micron stock doesn't look terribly attractive. Earnings for the past 12 months are only $4.7 billion, giving the stock about a 25x P/E ratio -- not obscenely expensive, but certainly not "cheap." Free cash flow at the memory maker is even worse, just $606 million for the past year, resulting in a price-to-free cash flow ratio of... 190! (Which does seem kind of obscene.) Still, Micron's a cyclical stock in the famously cyclical semiconductor industry, where "cheap" stocks can become "expensive," and vice versa, in the blink of an eye. The best time to buy such stocks can be when their valuations look the worst -- like today. Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Micron Stock Popped Today was originally published by The Motley Fool Sign in to access your portfolio
